Johnson & Johnson Total Change in Assets/Liabilities 2010-2025 | JNJ

Johnson & Johnson annual/quarterly total change in assets/liabilities history and growth rate from 2010 to 2025. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
  • Johnson & Johnson total change in assets/liabilities for the quarter ending June 30, 2025 was $-15.942B, a 1917.97% increase year-over-year.
  • Johnson & Johnson total change in assets/liabilities for the twelve months ending June 30, 2025 was $-24.094B, a 3870.58% decline year-over-year.
  • Johnson & Johnson annual total change in assets/liabilities for 2024 was $1.848B, a 26.29% decline from 2023.
  • Johnson & Johnson annual total change in assets/liabilities for 2023 was $2.507B, a 162.24% decline from 2022.
  • Johnson & Johnson annual total change in assets/liabilities for 2022 was $-4.028B, a 6.02% decline from 2021.
Johnson & Johnson Annual Total Change in Assets/Liabilities
(Millions of US $)
2024 $1,848
2023 $2,507
2022 $-4,028
2021 $-4,286
2020 $2,753
2019 $3,845
2018 $-28
2017 $11,258
2016 $-1,784
2015 $1,647
2014 $-855
2013 $-959
2012 $-969
2011 $1,523
2010 $-858
2009 $1,339
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $425.048B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $696.621B 45.58
AbbVie (ABBV) United States $368.080B 19.67
Novartis AG (NVS) Switzerland $267.517B 14.49
Roche Holding AG (RHHBY) Switzerland $256.819B 0.00
Novo Nordisk (NVO) Denmark $247.093B 14.96
Merck (MRK) United States $212.287B 11.12
Pfizer (PFE) United States $141.684B 7.35
Sanofi (SNY) France $123.512B 12.24
Bayer (BAYRY) Germany $32.616B 6.15
Innoviva (INVA) United States $1.256B 12.38